Eton Pharmaceuticals earns a Buy rating as scalable commercial operations, expanding margins and pipeline launches support continued growth. Third-quarter revenue rose 158% to $57.9 million, with a 49% adjusted EBITDA margin; 2026 revenue guidance increased to more than $175 million. LIBERVANT and ASN-001 are the main growth drivers, with potential launches in 2027 and 2028, respectively.


